Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stopping the biologic clock for globin gene switching.

S P Perrine1, D V Faller, P Swerdlow

  • 1Children's Hospital Oakland Research Institute, California 94609.

Annals of the New York Academy of Sciences
|January 1, 1990
PubMed
Summary

Butyric acid compounds can inhibit the fetal to adult globin gene switch, potentially treating beta-thalassemia by maintaining fetal globin expression and silencing abnormal adult globin genes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of DNA test for hip dysplasia failed in Danish Labrador Retrievers.

Animal genetics·2020
Same author

Transfer and expression of the human multiple drug resistance gene as potential human gene therapy.

Cytotechnology·2012
Same author

Excess alpha chain synthesis relative to beta chain synthesis in thalassaemia major and minor.

Nature·2010
Same author

Introduction.

Kronos (Bellville, South Africa)·2009
Same author

Anthropology and portrait photography: Gustav Fritsch's "Natives of South Africa," 1863-1872.

Kronos (Bellville, South Africa)·2009
Same author

Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives.

Current pharmaceutical design·2008

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • The switch from fetal (gamma) to adult (beta) globin production is a critical developmental process.
  • Beta-thalassemias involve defective adult beta-globin gene expression, leading to reduced protein production.
  • Interfering with this developmental switch offers a therapeutic strategy for beta-thalassemia.

Purpose of the Study:

  • To identify agents that can inhibit or reverse the gamma- to beta-globin gene switch.
  • To investigate the potential of butyric acid and related compounds in modulating globin gene expression.
  • To explore therapeutic approaches for beta-globin disorders by targeting the globin gene switch.

Main Methods:

  • Administration of specific agents during gestation in humans and in vivo fetal animal models.

Related Experiment Videos

  • In vitro studies using cultured erythroid cells from beta-thalassemia patients.
  • Analysis of globin gene expression (gamma-globin and beta-globin).
  • Investigation of molecular mechanisms including histone hyperacetylation and promoter activity.

    • Main Results:

    • Elevated plasma concentrations of identified agents inhibited the gamma- to beta-globin gene switch in developing humans.
    • Butyric acid compounds increased gamma-globin and decreased beta-globin expression in cultured cells.
    • In vivo infusion of butyrate compounds inhibited and, in some cases, reversed the globin switch in fetal lambs.
    • Histone hyperacetylation and effects on the gamma-globin promoter were identified as mechanisms.

    Conclusions:

    • Pharmacologic inhibition of the gamma- to beta-globin gene switch is a viable strategy.
    • Butyric acid and related compounds show promise for treating beta-thalassemia.
    • Targeting globin gene expression offers a potential future treatment for beta-globin disorders.